3-Iodothyronamine and Derivatives: New Allies Against Metabolic Syndrome?

In the two decades since its discovery, a large body of evidence has amassed to highlight the potential of 3-iodothyronamine (T1AM) as an antiobesity drug, whose pleiotropic signaling actions profoundly impact energy metabolism. In the present review, we recapitulate the most relevant properties of...

Descripción completa

Detalles Bibliográficos
Autores principales: Rutigliano, Grazia, Bandini, Lavinia, Sestito, Simona, Chiellini, Grazia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139928/
https://www.ncbi.nlm.nih.gov/pubmed/32183490
http://dx.doi.org/10.3390/ijms21062005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139928/
https://www.ncbi.nlm.nih.gov/pubmed/32183490
http://dx.doi.org/10.3390/ijms21062005

Ejemplares similares